Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are over 18 years old
- You are willing and able to sign a written consent form to participate
If you fall into Group A (relapsed/refractory patients):
- You have been diagnosed with classical Hodgkin lymphoma that has come back or stopped responding to treatment
- Tissue samples (taken when you were first diagnosed and when your disease returned) are available for testing
- A blood sample taken when your disease came back (before starting new treatment) is available
- You have had a PET scan available at the time of joining the study
- Your medical records, lab results, and scan results from diagnosis and when the disease returned are available
If you fall into Group B (patients who finished first treatment):
- You have been diagnosed with classical Hodgkin lymphoma
- You have completed your first course of standard treatment (chemotherapy, or chemotherapy combined with radiotherapy)
- A blood sample taken at least 30 days after your last chemotherapy session is available
- A tissue sample taken at diagnosis is available
- No further treatment is currently planned
- Your medical records, lab results, and scan results are available
- You are willing to provide blood samples over 6 months and attend regular check-up appointments
If you fall into Group C (patients receiving standard treatment):
- You have been diagnosed with classical Hodgkin lymphoma
- You are receiving standard treatment following recognised medical guidelines
- Your treatment details, response to treatment, and follow-up information are available
- A tissue sample taken at diagnosis is available
- A PET scan is available at the time of joining the study
Who may not be able to join:
- People diagnosed with a specific type called "nodular lymphocyte predominant Hodgkin lymphoma" are not eligible (other subtypes such as nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted are eligible — confirm with trial site if unsure of your subtype)
- People currently living with an active HIV, Hepatitis B, or Hepatitis C infection
- People who have another type of cancer that is not being treated with the aim of a cure
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Genetic Mutational Profiling of cHL at Progression
Can't join this trial?
Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.